Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.205 -0.095 (-1.14%)
Streaming Delayed Price Updated: 10:26 AM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Shares of BioCryst Pharmaceuticals Jumped Today
A day after the stock plummeted, it bounced back. 
Via The Motley Fool
Analyst Sees Attractive Entry Opportunity After BioCryst's Pipeline Setback
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
 
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Why BioCryst Pharmaceuticals Stock Is Sinking Today
Investors didn't like the drugmaker's Q4 update. 
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why BioCryst Pharmaceuticals Stock Is Sliding Today
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported worse-than-expected earnings results< 
Via Benzinga
Biocryst Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
BioCryst Shelves Development Of Rare Blood Disorder Candidate
 
Via Benzinga
Expert Ratings for BioCryst Pharmaceuticals
Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter: 
Via Benzinga
BioCryst Pharmaceuticals Stock Is Tumbling: What's Going On?
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday after the company announced preliminary fourth-quarter and full 
Via Benzinga
TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets
Tesla (TSLA) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk's Twitter purchase. 
Via InvestorPlace
Why Is Getaround (GETR) Stock Up 6% Today?
Getaround (GETR) stock is on the move Thursday with heavy trading despite a lack of recent news concerning the car-sharing service. 
Via InvestorPlace
BCRX Stock Sinks as BioCryst Discontinues Drug Development
BioCryst Pharmaceuticals (BCRX) stock is falling on Thursday after revealing it's no longer developing BCX9930 for competitive reasons. 
Via InvestorPlace
Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
4 Analysts Have This to Say About BioCryst Pharmaceuticals
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
What's Going On With BioCryst Pharmaceuticals Stock Today?
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported third-quarter financial results. 
Via Benzinga
BioCryst Pharmaceuticals: Q3 Earnings Insights
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
The company scrapped its hereditary angioedema drug due to safety issues. 
Via Investor's Business Daily
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.